No Data
Fuxiang Pharmaceutical: Report for the third quarter of 2024
Jiangxi Fushine Pharmaceutical (300497.SZ) released its performance for the first three quarters, with a net loss of 62.075 million yuan.
Jiangxi Fushine Pharmaceutical (300497.SZ) released the report for the first three quarters of 2024, during which the company achieved revenue...
Jiangxi Fushine Pharmaceutical (300497.SZ): The net loss in the third quarter was 39.6157 million yuan.
GeLongHui October 23rd | Jiangxi Fushine Pharmaceutical (300497.SZ) released the third quarter report of 2024, with revenue of 0.294 billion yuan, a year-on-year decrease of 31.65%; net income attributable to shareholders of the listed company -39.6157 million yuan; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses -44.7531 million yuan; basic earnings per share -0.07 yuan.
Fushine Pharmaceutical Unit Gets GMP Certificate
Jiangxi Fushine Pharmaceutical (300497.SZ): Xiangtai Science passes pharmaceutical GMP compliance inspection.
Gelonghui September 30th | Jiangxi Fushine Pharmaceutical (300497.SZ) announced that its wholly-owned subsidiary, Jiangxi Xiangtai Life Science Co., Ltd. (referred to as "Xiangtai Science"), recently received the "Jiangxi Provincial Drug Administration Drug GMP Compliance Inspection Results Notification" (No. 44, 2024) issued by the Jiangxi Provincial Drug Administration. This inspection found that the aseptic active pharmaceutical ingredient (Tazobactam Sodium, W04 workshop, Tazobactam Sodium production line) complies with drug GMP.
Jiangxi Fushine Pharmaceutical (300497.SZ): Terminates the implementation of the second phase of the employee stock ownership plan.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced on September 30th that the company held the 23rd meeting of the fourth board of directors on September 30, 2024. The meeting reviewed and approved the resolution on terminating the implementation of the second phase of the employee stock ownership plan. In accordance with the authorization of the shareholders' meeting, the board of directors agreed to terminate the implementation of the company's second phase of employee stock ownership plan, along with the corresponding 'Management Measures for the Second Phase of Employee Stock Ownership Plan' and other documents. Given the significant changes in the current market environment compared to when the employee stock ownership plan was formulated, in order to better achieve the company's strategic development goals and to safeguard the interests of the company, shareholders, and employees.
The Market Doesn't Like What It Sees From Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Revenues YetNo Data
No Data
